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Alzheimer’s disease (AD) is characterized by extracellular amyloid- (A) deposits andmicroglia-dominated inflammatory activation.
Innate immune signaling controlsmicroglial inflammatory activities andA clearance. However, studies examining innate immunity in
A pathology and neuronal degeneration have produced conflicting results. In this study, we investigated the pathogenic role of innate
immunity in AD by ablating a key signaling molecule, IKK, specifically in the myeloid cells of TgCRND8 APP-transgenic mice. Defi-
ciency of IKK inmyeloid cells, especiallymicroglia, simultaneously reduced inflammatory activation andA load in thebrain and these
effects were associated with reduction of cognitive deficits and preservation of synaptic structure proteins. IKK deficiency enhanced
microglial recruitment to A deposits and facilitated A internalization, perhaps by inhibiting TGF--SMAD2/3 signaling, but did not
affect A production and efflux. Therefore, inhibition of IKK signaling in myeloid cells improves cognitive functions in AD mice by
reducing inflammatory activation and enhancing A clearance. These results contribute to a better understanding of AD pathogenesis
and could offer a new therapeutic option for delaying AD progression.
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Introduction
Microglia-dominated neuroinflammation is a hallmark of Alz-
heimer’s disease (AD) (Akiyama et al., 2000; Wyss-Coray and
Rogers, 2012). Positron emission tomography studies have
shown that microglial activation correlates with disease progres-
sion in AD patients (Cagnin et al., 2001; Edison et al., 2008;
Okello et al., 2009). In AD mouse models, which overexpress
Alzheimer’s APP in neurons, microglia are observed to be acti-
vated and recruited to deposits of pathogenic amyloid  peptides
(A) (Bolmont et al., 2008; Meyer-Luehmann et al., 2008).
Increasing evidence suggests that the innate immune system
drives chronic neuroinflammation, controls cerebral A load,
and subsequently affects neuronal degeneration in AD. In APP-
transgenic mice, a deficiency in certain innate immune mole-
cules, such as CD14 (Reed-Geaghan et al., 2010), Toll-like
receptor 2 (TLR2) (Liu et al., 2012), TLR4 (Song et al., 2011),
myeloid differentiation factor 88 (MyD88) (Hao et al., 2011), and
interleukin receptor-associated kinase 4 (IRAK4) (Cameron et
al., 2012), attenuates the degree of neuroinflammation, shifts mi-
croglial activation from proinflammatory to anti-inflammatory
pathways, or both. However, the results of studies of the effects of
innate immunity on A pathology and neuronal degeneration in
AD mice are inconclusive and sometimes contradictory. For ex-
ample, one study showed that TLR4 deficiency exaggerates A
deposition (Tahara et al., 2006), whereas another study showed
that a deficiency in theTLR4 coreceptorCD14 exerts the opposite
effect by reducing the cerebral A load (Reed-Geaghan et al.,
2010). Several studies have found that a deficiency in MyD88 or
itsdownstreamsignalingmolecule, IRAK4, attenuatesApathology
andneuronal damage inAPP-transgenicmice (Hao et al., 2011; Lim
et al., 2011; Cameron et al., 2012), but other reports state that wild-
typeMyD88 is necessary for clearingA from thebrain andprotect-
ing cognitive function (Michaud et al., 2011 and 2012). Although it
should be noted that these studies differ in methods and animal
models, the apparently conflicting results remain puzzling; there-
fore,neuroscientists are actively investigatingwhether innate immu-
nity is “friend or foe” in AD pathogenesis.
To explore this question, we examined the role of inhibitor of
NF-B (IB) kinase- (IKK), one of the key signalingmolecules
Received April 3, 2014; revised July 23, 2014; accepted Aug. 14, 2014.
Author contributions: Y.L. and K.F. designed research; Y.L., X.L., W.H., Y.D., and R.S. performed research; L.F.,
M.P.,M.D.M., andK.F. contributedunpublished reagents/analytic tools; Y.L., X.L.,W.H., Y.D., andR.S. analyzeddata;
Y.L. wrote the paper.
This workwas supported by Alzheimer Forschung Initiative e.V. (to Y.L.); Fritz Thyssen Stiftung (to Y.L. and K.F.);
Medical Faculty of University of the Saarland throughHOMFOR2013 (to Y.L.); and Forschungspreis 2011 der Freunde
des Universita¨tsklinikums des Saarlandes (to W.H.). We thank D. Westaway (University of Toronto, Canada) for
providing TgCRND8 APP transgenic mice; Junfa Li (Capital University of Medical Sciences, Beijing, China) for help
with the technical equipment; and Mirjam Mu¨ller, Rebecca Lancaster, and Andrea Schottek for excellent technical
assistance.
The authors declare no competing financial interests.
*Y.L. and X.L. contributed equally to this work.
Correspondence should be addressed to Dr. Yang Liu, Department of Neurology, University of the Saarland,
Kirrberger Strae, 66421 Homburg/Saar, Germany. Tel: 0049-6841-1624260; Fax: 0049-6841-1624175; E-mail:
a.liu@mx.uni-saarland.de.
DOI:10.1523/JNEUROSCI.1348-14.2014
Copyright © 2014 the authors 0270-6474/14/3412982-18$15.00/0
12982 • The Journal of Neuroscience, September 24, 2014 • 34(39):12982–12999
downstream of TLRs-MyD88-IRAK4 in microglia (Kawai and
Akira, 2011). Activated IKK phosphorylates IB and triggers its
degradation by proteasomes and this process results in transloca-
tion of NF-B to the nucleus and the induction of NF-B-
dependent transcription of a wide range of immune and
inflammatory genes (Lawrence, 2009). We used the Cre-Lox
technique to knock out the ikbkb gene (encoding IKK) specifically
in the myeloid cell lineage (including microglia, macrophages, and
monocytes) inAPP-transgenicmiceunderphysiological conditions.
As shown by Mildner et al. (2011), engraftment of bone marrow
(BM)-derived cells in the brain parenchyma of AD mice does not
occur normally during disease progression without precondi-
tioning the brain (e.g., by irradiation). In our APP-transgenic
mice, no peripheral myeloid cells should infiltrate the brain un-
der physiological conditions, and the effects of the deficiency in
IKK in endogenousmicroglia in thesemice should be apparent.
Here, we report the results of the study.
Materials andMethods
Mice. TgCRND8 APP-transgenic mice (app tg) on a 129 background
(continuously interbred for9 generations to reach the genetic cognate)
expressing a transgene incorporating both the Indianamutation (V717F)
and the Swedish mutations (K670N/M671L) in the human app gene
under the control of hamster prion protein (PrP) promoter were kindly
provided by D. Westaway (University of Toronto). In this mouse strain,
the A load does not differ betweenmale and female mice (Chishti et al.,
2001). Ikbkb fl/fl mice carrying loxP site-flanked ikbkb alleles on a
C57BL/6N genetic background were kindly provided by M. Pasparakis
(University of Cologne; Pasparakis et al., 2002). Ikbkb fl/fl mice express
normal levels of IKK. LysM-Cre knock-in mice (LysM-Cre/) ex-
pressing Cre from the endogenous lysozyme 2 gene locus were obtained
from The Jackson Laboratory (stock number 004781; Clausen et al.,
1999) and were back-crossed to C57BL/6J mice for 6 generations.
Therefore, myeloid cell type (e.g., microglia and macrophages)-specific
IKK-deficient (ikbkb fl/flCre/) mice were generated by breeding
ikbkb fl/fl mice and LysM-Cre knock-in mice. APP-transgenic mice defi-
cient in IKK specifically in myeloid cells (app tgikbkb fl/flCre/) were
then established by cross-breeding APP-transgenic mice with ikbkb fl/fl
and LysM-Cremice on a constantC57BL/6129 (1:1) genetic background.
All mice from the same litter were used for the study without any exclu-
sion so that the phenotype of APP-transgenicmice with or without IKK
ablation in myeloid cells was compared only between siblings. To dem-
onstrate the cell-specific expression of Cre recombinase, we cross-bred
LysM-Cre mice to ROSAmT/mG Cre report mice (The Jackson Labora-
tory; stock number 007676), which express cell membrane-targeted
tomato fluorescent protein (TFP) before Cre exposure and express cell-
membrane-targeted GFP in Cre-expressing cells. To track microglia
and brain macrophages with deficiency of IKK in the AD mice,
app tgikbkb fl/flCre/ mice were further mated to ROSAmT/mG mice to
obtain app tgikbkb fl/flROSAmT/mGCre/ mice. To demonstrate the
chemokine (C-Cmotif) receptor 2 (CCR2)-positive cells in the ADmice,
we cross-bred TgCRND8 APP-transgenic mice to CCR2-RFP mice (The
Jackson Laboratory; stock number 017586), in which the CCR2 coding
sequence has been replaced with an RFP-encoding sequence. All animal
experiments were approved by the regional ethical committee in Saar-
land, Germany.
Cell isolation and primary microglial culture. Primary microglia were
isolated from brains of newborn mice resulting from crosses of ikbkb fl/fl
and LysM-Cre knock-in mice (ikbkb fl/flCre / and ikbkb fl/flCre/).
Microglia were cultured in DMEM (Life Technologies) supplemented
with 10% FCS (PAN Biotech) in 25 cm2 flasks (BD Biosciences) accord-
ing to a published protocol (Liu et al., 2005). As shown by flow cytom-
etry,98% of microglia were CD11b.
Preparation of A peptides. The 42 aa form of human A (A42) was
kindly provided by Dr. L. Fu¨lo¨p (Albert Szent Gyorgyi Medical Univer-
sity, Szeged, Hungary). The oligomeric and fibrillar As were prepared
according to a published protocol (Dahlgren et al., 2002). Fluorescent A
was prepared by mixing HiLyte Fluor 488-labeled human A42 (AnaSpec)
and unlabeled A at a ratio of 1:10. Endotoxin concentrations of peptide
samples were0.01 EU/ml, as determined by the Limulus amebocyte lysate
assay (Lonza). Western blot analysis confirmed that HiLyte Fluor 488-
conjugated and nonconjugated forms of A42 peptides had similar oligo-
meric conformations.
Flow cytometric analysis of HiLyte Fluor 488-conjugated A42 internal-
ization in primary microglia. To investigate effects of IKK on microglial
internalization of A, IKK-deficient and wild-type primary microglia
cultured in a 24-well plate (BD Biosciences) at a density of 3 105 cells
per well were treated with 0.2 or 1.0 M HiLyte Fluor 488-conjugated
A42 aggregates for various time periods, as indicated in the Results. To
investigate effects of blocking TGF--SMAD2/3 signaling on A inter-
nalization, wild-type microglia were pretreated with the activin-like
kinase-5 (ALK5) inhibitors SB-505124 and SB-431542 at 0, 0.004, 0.02,
0.1, 0.5, or 1.0M for 1 h, followed by incubationwith 1.0M fluorescent
oligomeric A42 aggregates for 6 h in the presence of pretreated inhibi-
tors. Thereafter, microglia were washed with a 1 solution of PBS and
detached from the plate with trypsin-EDTA (Life Technologies). The
mean fluorescence intensity (mFI) of internalized fluorophore-
conjugated A42 and the percentages of positive cells with intracellular
proteins were immediately determinedwith a FACSCanto II flow cytom-
eter (BD Biosciences). To examine the surface binding of A, we incu-
bated cells with 1.0MHiLyte Fluor 488-conjugated A42 aggregates for
2 h on ice and then analyzed them for mFI.
Western blot detection of phosphorylated p65 and SMAD proteins in
microglia. Primary microglia were cultured in the 6-well plate (BD Bio-
sciences) at a density of 1  106 cells/well For detection of phosphory-
lated and total amount of the p65 component of the NF-B complex,
IKK-deficient and wild-type cells were activated with 10M oligomeric
A42 for 12 min. For detection of phosphorylated and total amount of
SMAD2 and SMAD5, IKK-deficient and wild-type cells were activated
with recombinant mouse TGF-1 (R&D Systems) at 0, 1, and 10 ng/ml
for 30 min. To test the inhibitory effects of ALK5 inhibitors, wild-type
primary microglia were pretreated with SB-505124 or SB-431542 at 0,
0.02, and 0.1M for 1 h and then treatedwith 1 ng/ml TGF-1 for 30min
in the presence of inhibitors. After treatments, cells were immediately
lysed in buffer (50mMTris/HCl, pH7.4, 2mMEDTA, 50 nMokadaic acid,
5 mM sodium pyrophosphate, 50 mMNaF, 1 mMDTT, 1% Triton X-100,
and protease inhibitor mixture; Roche Applied Science). For Western
blot, rabbitmonoclonal antibodies against phosphorylated and total p65,
SMAD2, and SMAD5, and-actin (clone 93H1,D14E12, 138D4,D43B4,
D5B10, D4G2, and 13E5, respectively; Cell Signaling Technology) were
used. Western blots were visualized via the ECL method (PerkinElmer).
Densitometric analysis of band densities was performed with ImageJ
software version 1.4.3. For each sample, the protein level was calculated
as a ratio of target protein/-actin from that sample.
Barnes maze test. The Barnes maze test was used to assess the cognitive
function of various APP-transgenic and wild-type littermate mice ac-
cording to an established protocol (Hao et al., 2011; Liu et al., 2012). The
test involved 5 d of acquisition training with 2 trials per day. For each
trial, latency to enter the escape chamber and distance traveled were
recorded by EthoVision XT version 7.0 tracking software (Noldus Infor-
mation Technology), and an average time for latency and total distance
was obtained by averaging the results of the 2 daily trials. Twenty-four
hours after the last training day, a probe trial was performed, inwhich the
escape chamber was removed, the mice were placed in the center of the
maze just as during acquisition training, and eachmousewas given 5min
to explore the maze. During the probe phase, we recorded the time mice
spent in the target zone, which is adjacent to the escape hole and its two
neighboring holes, and the frequency with which mice visited the target
zone and the nontargeting zone, which surround other holes far from the
escape hole (see Fig. 4A). The experimenter was blinded to the genotypes
of the mice during the entire test.
Positive selection of CD11b microglia/brain macrophages in the adult
mouse brain. To determine the gene expression and cell surface antigen
expression in microglia/brain macrophages, we carefully dissected the
entire cerebrum from3-or 6-month-oldAPP-transgenicmicewithorwith-
out adeficiency inmyeloid IKK (ikbkb fl/flCre /or ikbkb fl/flCre/).We
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prepared a single-cell suspension with the Neural Tissue Dissociation Kit
(papain-based) and removed myelin by using Myelin Removal Beads II
(both from Miltenyi Biotec) according to the manufacturer’s protocols.
After pelleting cells by centrifugation, we added 80 l of blocking buffer
containing 25 g/ml rat anti-mouse CD16/CD32 antibody (2.4G2; BD
Biosciences) and 10% FCS to prevent nonspecific binding. Thirty min-
utes after blocking at 4°C, we added 20 l of MicroBeads-conjugated
CD11b antibody (Miltenyi Biotec) directly to the cells. After 1 additional
hour of incubation at 4°C, cells were washed with buffer and loaded onto
a MACS LS Column (Miltenyi Biotec) for separation. Lysis buffer was
immediately added to both CD11b and CD11b cells for isolation of
total RNA with the RNeasy Plus Mini Kit (Qiagen); alternatively,
CD11b cells were used for flow cytometric analysis after cells were
stained with fluorescence-labeled anti-CD45 antibody (clone 30-F11
eBioscience) or CD11b cells were used for Western blot detection of
IKK after cells were lysed in buffer (50 mM Tris/HCl, pH 7.4, 145 mM
NaCl, 1% Triton-100, and protease inhibitor mixture; Roche Applied
Science) and the rabbit monoclonal antibody against IKK (clone Y466;
Abcam) was used to blot the membrane.
Tissue collection for pathological analysis. Animals were put to death at
6months of age by inhalation of isoflurane (Abbott Laboratories).Whole
blood was collected by intracardial puncture and placed into EDTA-
containing Eppendorf tubes. Mice were then rapidly perfused transcar-
dially with ice-cold PBS, and the brain was removed and divided. The left
hemibrain was immediately fixed in 4% PFA (Sigma-Aldrich) for histo-
logical analysis. A 0.5-mm-thick piece of tissuewas sagittally cut from the
right hemibrain. The cortex and hippocampus were carefully separated
and homogenized in TRIzol (Life Technologies) for RNA isolation. The
remainder of the right hemibrain was snap-frozen in liquid nitrogen for
biochemical analysis.
Brain homogenates and A and TNF- ELISA. The brain was homog-
enized as described previously (Liu et al., 2012). Briefly, frozen hemi-
spheres were bounce-homogenized in TBS containing a protease
inhibitormixture (Roche Applied Science) and centrifuged at 16,000 g
for 30 min at 4°C. The supernatant (TBS-soluble fraction) was collected
and stored at 80°C. The pellets were resuspended in TBS plus 1%
Triton X-100 (TBS-T), sonicated for 5 min in a 4°C water bath, and
centrifuged at 16,000 g for another 30min at 4°C. The supernatant was
collected and stored at80°C as the TBS-T-soluble fraction. The pellets
were extracted for a third time with an ice-cold guanidine buffer (5 M
guanidine HCl/50 mM Tris, pH 8.0, herein referred to as the guanidine-
soluble fraction). The protein concentration of all samples wasmeasured
with the Bio-Rad Protein Assay. The A concentrations in three separate
fractions of brain homogenates were determined by A42 and A40
ELISA kits (both from Life Technologies). The concentration of aggre-
gated A in TBS-T-soluble fraction was also assayed with Oligomeric
Amyloid- ELISAKit (Biosensis). The TNF- concentration in the TBS-
soluble brain fraction was measured by ELISA (eBioscience). Results
were normalized on the basis of the sample’s protein concentration.
Western blot analysis of synaptic proteins. To detect synaptic proteins in
the brain, we used 10% Tris-glycine PAGE to separate TBS-T-soluble
brain homogenate derived from APP-transgenic and non-APP-
transgenic littermate mice differing in IKK expression. Western blots
and analysis were performed as described in the section “Western blot
detection of proteins inmicroglia” using the following antibodies:mouse
monoclonal anti-PSD-95 (clone 6G6-1C9;Abcam) and rabbit polyclonal
anti-the mammalian homolog of unc-18 protein (Munc18)-1 (Cell Sig-
naling Technology). The mouse monoclonal anti--tubulin (clone
DM1A; Abcam) was used as a protein loading control.
Immunohistochemistry. Four percent PFA-fixed left hemispheres were
embedded in paraffin and serial 40-m-thick sagittal sections were cut
and mounted on glass slides. Immunohistochemical staining with the
primary antibody, rabbit anti-ionized calcium-binding adaptermolecule
1 (Iba-1) (1:500; Wako Chemicals), or mouse monoclonal anti-human
A antibody (clone 6F/3D; Dako), was performed on these sections with
the VectaStain Elite ABC kit (Vector Laboratories). Diaminobenzidine
(Sigma-Aldrich) was used as the chromogen and counterstaining was
performed with hematoxylin for Iba-1 staining. To detect proliferating
microglia, we added the rabbitmonoclonal antibody (clone SP6; Abcam)
directed against Ki67 to sections that had been already stained with Iba-1
antibodies but before hematoxylin counterstaining. Thereafter, we used
the VectaStain ABC-AP kit and the VECTOR Blue Alkaline Phosphatase
Substrate kit without hematoxylin counterstaining. Ki67 staining was
visualized in blue. To investigate potentially brain-infiltrating peripheral
leukocytes, we performed immunohistochemical staining with rat anti-
mouse CD45 (clone 30-F11; BD Biosciences), rabbit anti-CD3 poly-
clonal antibody (catalog #ab5690; Abcam), rat anti-mouse neutrophil
(clone RM0028-3G23; Novus Biologicals), and mouse anti-CD68 (clone
KP1; Abcam) just aswe did for Iba-1 staining except that the hematoxylin
counterstaining was skipped to improve the sensitivity for observing the
positive staining.
Immunofluorescent staining. To demonstrate the colocalization of
IKK or GFP and various cellularmarkers (e.g., Iba-1, S100, andNeuN),
we used paraffin-embedded sections. The primary antibodies rabbit
polyclonal anti-IKK (catalog #NB600-477; Novus Biologicals) and rab-
bit or chicken polyclonal anti-GFP (catalog #ab290 and catalog
#ab13970; Abcam) were first incubated with deparaffinized brain sec-
tions and thereafter with Alexa Fluor 488-conjugated goat anti-rabbit
IgG or chicken IgY. After thorough washing, additional antibodies
against various cellular markers (mouse monoclonal anti-Iba-1, clone
20A12.1; Millipore; mouse monoclonal anti-S100, clone 4C4.9; Abcam;
ormousemonoclonal anti-NeuN, clone A60;Millipore) were added and
were visualized with relevant Alexa Fluor 546-conjugated second anti-
bodies (all second antibodies were from Life Technologies). To detect
CCR2-RFP cells in the brain, we used brain sections from 6-month-old
BM chimera APP-transgenic mice, which were constructed as in our
published study (Hao et al., 2011) with ROSAmT/mG mice as the BM
donor, as positive controls. A rabbit polyclonal anti-RFP and its variants
(e.g., tdTomato; Rockland Immunochemicals) were used as the first an-
tibody and Alexa Fluor 546-conjugated anti-rabbit IgG was used as the
second antibody (Life Technologies).
Congo red staining. To identify compacted amyloid in a -sheet sec-
ondary structure in the brain tissue, we stained paraffin-embedded sec-
tions as described in the section of “Immunohistochemistry”withCongo
red according to the standard laboratory procedures (Wilcock et al.,
2006). To demonstrate the amyloid A deposits in the blood vessel, we
cooked Congo red-stained sections in citrate buffer and then treated
them with pepsin (Life Technologies) for the antigen retrieval. After
being blocked in goat serum, the sections were incubated with a rabbit
polyclonal against collagen type IV (catalog #ab6586; Abcam) as the first
antibody and Alexa Fluor 488-conjugated goat anti-rabbit IgG as the
second antibody.
Histological image acquisition and analysis. All images were acquired
with a Zeiss AxioImager.Z2 microscope equipped with a Stereo Investi-
gator system (MicroBrightField).Weused the stereological technique for
all histological analyses and were kept blinded to the genotype of mice
during the whole experiment. Briefly, after systematic random sampling
of every 10th section throughout the entire hippocampus and the cortex,
we used the Optical Fractionator (MicroBrightField) as a stereological
probe to quantify Iba-1-labeled cells with 120  120  18 m of a
dissector and 400  400 m of a sampling grid. In each dissector, only
Iba-1 cells with clear hematoxylin nucleus staining were counted. The
estimated coefficient of error was0.05. Volumes of A, Congo red stain-
ing, and brain tissues (hippocampus and cortex) were estimated with the
Cavalieri probe (Gundersen and Jensen, 1987) with 20 m of a grid size,
which provided coefficient of error estimates of 0.04. The A load was
demonstrated as the ratio of A volume to relevant brain tissue volume.
The proliferating microglia, which appeared with typical brown mi-
croglial processes and dark blue nuclei, were counted in the total hip-
pocampus area in the randomly selected sections as described in the
preceding paragraph. CD45, CD3, neutrophil, and CD68 cells
were counted in randomly selected sections of the entire hemisphere.
Because the cell numbers were low, we did not use stereological analysis,
which requires a larger number of countable cells so that the random
paradigm can be applied. Data were recorded as the number of antibody-
labeled cells divided by the full area (in square millimeters) of interest.
To analyze the distribution of A plaque size, we acquired images of
hippocampus after Congo red staining with a 10 objective (Carl Zeiss)
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using the Virtual Tissue Module (MicroBrightField). The hippocampus
was delineated and the area of individual plaques was determined after
performing histogram-based segmentationwith Image-Pro Plus 6.0 soft-
ware (Media Cybernetics).
Confocalmicroscopy. To investigate the relationship betweenmicroglia
and A deposits, we costained four equidistant (120 m interval) serial
sections from each mouse (see the section of “Immunohistochemistry”)
with rabbit Iba-1 (Wako Chemicals) and monoclonal anti-A (clone
6F/3D; Dako) and then with Alexa Fluor 488-conjugated or Cy3-
conjugated second antibodies. Under a Zeiss LSM 510 Meta Confocal
Microscope with a 40 objective, A deposits labeled with Cy3 were
imaged after excitation with a 543 nm laser. Thereafter, we performed
Z-stack serial scanning at 1m intervals from15 to15munder the
excitation of 488 and 543 nm lasers. Five randomly chosen areas from
each section were analyzed. To count the number of Iba-1 cells that
colocalized with A deposits, we color-coded the images of Alexa Fluor
488 (Iba-1) and Cy3 (A) and reconstructed a 3D structure with the
Imaris 7.2.3 software (Bitplane). At the same time, the area of A from
each layer of serial scanning was determined with ImageJ software. Fi-
nally, the total number of microglia in each section was normalized by
the total area of A deposits.
To demonstrate the morphology of microglia with and without IKK
ablation around the same A plaque in app tgikbkb fl/flROSAmT/mGCre/
mice, we costainedGFP, which represented Cre-mediated gene recombina-
tion and IKK ablation, and Iba-1 inAlexaFluor 488 andCy3 fluorescence,
respectively, and A with the blue alkaline phosphatase substrate (the
detailed staining procedure is described in the section of “Immunohis-
tochemistry”). Under confocal microscopy, we first identified the blue
A deposits using the bright field and then imaged microglia under the
excitation of 488 and 543 nm lasers.
Purification of membrane components and - and -secretase activity
assays. Membrane components were purified from 6-month-old APP-
transgenic and nontransgenic littermate mouse brains and - and
-secretase activities were measured by incubating the crude membrane
fraction with secretase-specific FRET substrates according to our estab-
lished methods (Hao et al., 2011; Xie et al., 2013).
Reverse transcription and quantitative PCR for analysis of gene tran-
scripts. For transcription analysis, total RNAwas extracted from the brain
homogenate in TRIzol and from brain cells in the lysis buffer. First-
strand cDNA was synthesized by priming total RNA with hexamer ran-
dom primers (Life Technologies) and using Superscript III reverse
transcriptase (Life Technologies). For quantification of gene transcripts,
real-time PCRwas performed with SYBR green (Roche Applied Science)
or TaqMan probes (Life Technologies) with the 7500 Fast Real-Time
PCR System (Life Technologies). The primer sequences for detecting
transcripts of tnf-, interleukin (il)-1, inducible nitric oxide synthase
(inos), chemokine (C-C motif) ligand 2 (ccl2), il-10, and gapdh were the
same as those used in our earlier study (Liu et al., 2006). TaqMan gene
expression assays from Life Technologies were used to measure tran-
scripts of the following genes:mouse tnf-, il-1,mannose receptor C type
1 (mrc1), arginase (arg)1, chitinase-3-like protein 3 (chi3l3), cd36, scaven-
ger receptor A (sra), insulin-degrading enzyme (ide), neprilysin (nep), the
receptor for advanced glycation end products (rage), low-density lipoprotein
receptor-related protein 1 (lrp1), cd40, transforming growth factor 1 (tgf-
1), tgf- receptor type I and II (tgf-r1 and r2), gapdh, and 18s RNA. For
the ikbkb transcript detection, the Taqman gene expression assay
(Mm01222249_m1) was used with the amplified PCR product overlap-
ping 6–7 exon boundary of ikbkb.
The amount of double-stranded PCR product synthesized in each
cycle was measured by detecting the FAM dye freed from the TaqMan
probes or SYBR green, which binds to double-stranded DNA. Threshold
cycle (Ct) values for each test gene from the replicate PCRs were normal-
ized to the Ct values for 18s RNA or gapdh control from the same cDNA
preparations. Transcription ratios were calculated as 2 (Ct), whereCt is
the difference between Ct (18s or gapdh) and Ct (test gene).
Statistics. Data shown in the figures are presented asmean	 SEM. For
multiple comparisons, we used one-way or two-way ANOVA followed
by Bonferroni’s, Tukey’s honestly significant difference, or Tamhane’s
T2 post hoc test (the choice of post hoc test depended on the result of
Levene’s test for homogeneity for determining the equality of variances).
Two independent-samples t tests were used to compare means for two
groups. All statistical analyses were performedwith SPSS version 19.0 for
Windows (IBM). Statistical significance was set at the level of p 0.05.
Results
Establishment of APP-transgenic mice with IKK deficiency
in myeloid cells (endogenous microglia in the brain)
To ablate IKK specifically in the myeloid cell lineage, especially
in microglia, we cross-bred TgCRND8 APP-transgenic mice
(apptg) to ikbkb-floxed mice (ikbkb fl/fl) and LysM-Cre knock-in mice
(LysM-Cre/). In the brains of 3-month-old apptgikbkb fl/flCre/
mice, immunofluorescencestainingconfirmedthatIKKproteinlevels
weregreatlyreducedbyCre-mediatedgene recombination in Iba-1
cells in the parenchyma, which represent endogenous microglia
and potentially infiltrating brain macrophages, but not in
NeuN cells (neurons) (Fig. 1A,B). IKK was undetectable in
S100-stained cells (astrocytes) (Fig. 1C). Accordingly, Western
blotting determined that the amount of IKK in CD11b cells
isolated from app tgikbkb fl/flCre/ mice was significantly less
than that in control cells isolated from app tgikbkb fl/flCre / lit-
termates (IKK/actin: 0.037	 0.004 vs 0.051	 0.003; t test, p

0.022; Fig. 1D,E). Similarly, quantitative PCR analysis showed
that the levels of ikbkb transcripts in CD11b brain cells from
app tgikbkb fl/flCre/mice were 34.53%	 1.61% of the levels of
ikbkb transcripts from app tgikbkb fl/flCre / littermatemice (Fig.
1F). In contrast, in CD11b brain cells, including neurons, as-
trocytes, and oligodendrocytes, the levels of general ikbkb tran-
scripts were unaffected by Cre expression (Fig. 1F). In additional
experiments, we also measured IKK protein levels in CD11b
circulating monocytes and cultured BM-derived macrophages,
which had been prepared according to our established protocol
(Hao et al., 2011). LysM-Cre could more efficiently recombine
the floxed genes in these peripheral myeloid cells than in mi-
croglia (IKK/actin: 0.095 	 0.014 vs 0.332 	 0.034, t test,
p  0.001, in monocytes; 0.013 	 0.002 vs 0.266 	 0.063, t
test, p 
 0.013, in cultured macrophages derived from
app tgikbkb fl/flCre/ and app tgikbkb fl/flCre / littermates,
respectively). Our results were consistent with those of a pre-
vious published report stating that the rate of LysM-Cre-
mediated gene recombination is 40% in microglia and
60% in monocytes (Goldmann et al., 2013).
To further confirm the cell selectivity of Cre, we cross-bred
LysM-Cremice toROSAmT/mGCre reportermice (Muzumdaret al.,
2007). This report system confirmed that Cre recombinase was ac-
tive only in Iba-1 cells, not in S100 cells (data not shown).
It is known that LysM-Cre recombines floxed genes in my-
eloid cells outside of the brain, including monocytes, macro-
phages, and neutrophils (Clausen et al., 1999; Goldmann et al.,
2013). We wondered whether peripheral myeloid cells had mi-
grated into the brain and affected brain pathology in our APP
mice, although one published study found a negative answer to
this question (Mildner et al., 2011).We found no positive immu-
nohistochemical staining with neutrophil-specific or CD3-
specific antibodies in the brains of 6-month-old APP-transgenic
mice (data not shown). Therefore, we excluded the possibility of
brain infiltration of neutrophils and T-lymphocytes, both of
which are CD45. However, we did observe a fewCD45 cells in
the same brain; these cells were diffused or clustered within a
region of the brain parenchyma, but were not distributed
throughout the entire brain area where A was deposited. The
density of CD45 cells was 2.01	 0.42/mm2 in the hippocam-
pus and cortex of app tgikbkb fl/flCre/ mice and 1.88	 0.38/
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mm2 in the hippocampus and cortex of app tgikbkb fl/flCre /
mice (Fig. 2A,B; t test between two groups, p  0.05). In addi-
tion, we used flow cytometry to count fluorescence-labeled cells
and found that, in the CD11b brain cell populations derived
from app tgikbkb fl/flCre/, app tgikbkb fl/flCre /, and even
appwtikbkb fl/flCre /mice,2%of cells wereCD45. This ratio
did not differ between the three groups ofmice (Fig. 2C,D; one-way
ANOVA, p 0.05), butwas significantly higher in the experimental
autoimmune encephalitis mice than in appwtikbkb fl/flCre /mice
(10.30%	 0.54%, Bonferroni’s post hoc test, p  0.001). Experi-
Figure1. LysM-Cre efficiently excises the floxed ikbkbgene inmicroglia andbrainmacrophages.A–C, Brain sections derived from3-month-old ikbkb fl/flCre/ (IKKko) and ikbkb fl/flCre /
(IKKwt) mice were stained for IKK (in green) and various cellular markers: Iba-1, NeuN, and S100 (in red). In IKKwt brains, IKK was strongly stained in Iba-1 cells (closed arrowhead),
whereas in the IKKko tissue, IKK staining was absent in most Iba-1 cells (open arrowhead). IKK was labeled in all NeuN, but in no S100 cells in both IKKko and IKKwt tissues. To
determine the ablation efficiency of the ikbkb gene by Cre recombinase, CD11b and CD11b cells were isolated from the brains of these two groups of mice. IKK protein was detected and
quantified by Western blot (D–E; t test; n
 4 per group) and the ikbkb gene transcripts were measured by quantitative PCR (F; t test; n
 4 per group).
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mental autoimmune encephalitis is amousemodel ofmultiple scle-
rosis with infiltration of peripheral leukocytes in the CNS. We
considered these CD45/CD11b cells with limited numbers to be
potentially infiltrating brainmacrophages.
As an additional confirmation of the existence of brain macro-
phages in AD mice, we performed immunohistochemical staining
with a popularly used macrophage-recognizing antibody, anti-
CD68.We did not observe CD68 cells in the brain parenchyma of
either app tgikbkb fl/flCre/ or app tgikbkb fl/flCre /mice (data not
shown). We cross-bred TgCRND8 APP-transgenic mice to CCR2-
RFPmice (Saederup et al., 2010). In 6-month-old APP-transgenic
mice heterozygous for the ccr2-rfp gene, we found no RFP cells
in the brain parenchyma and only a few cells in close proximity to
cerebral blood vessels (Fig. 2E; n 
 3). As a positive control we
used brains from 6-month-old BM chimera APP-transgenic
mice, which were constructed as described previously (Hao et al.,
2011) with ROSAmT/mG mice as the BM donor. The BM-derived
cells were distributed in the brain parenchyma and expressed
TFP, which reacts with the same antibody against RFP in CCR2-
RFPmice. The results of this experiment provide evidence for the
limited infiltration of brain macrophages in AD mice, given that
brainmacrophages are derived fromLy6ChighCCR2monocytes
(Mildner et al., 2007; Mizutani et al., 2012; Varvel et al., 2012).
We also investigated the effects of IKK deficiency in myeloid
cellsonperipheral inflammatory statusbymeasuringplasmaTNF-
levels. We observed no difference in plasma TNF- levels between
the fourmousegroups (appwtikbkb fl/flCre/, 35.38	 10.56pg/ml;
appwtikbkb fl/flCre /, 34.84	 11.39 pg/ml; app tgikbkb fl/flCre/,
32.68	 13.88 pg/ml; and app tgikbkb fl/flCre /, 35.88	 9.09 pg/
ml; one-way ANOVA, p 0.05; n
 9 per group.
Finally, we investigated the effects of IKK deficiency on mi-
croglial NF-B activation. Western blot analysis showed that
the amount of IKK protein detected in cultured primarymicro-
glia derived from ikbkb fl/flCre/ mice was 49.18%	 6.90%
of the amount detected in cultured microglia derived from
ikbkb fl/flCre /mice (Fig. 3A,B). The50% reduction in IKK
protein suppressed the phosphorylation of p65 in the NF-B
complex in the microglia both at the basal level and after activa-
tion with 10 M oligomeric A42 (the ratio of phosphorylated
p65 to total p65 was 0.40	 0.09 in ikbkb fl/flCre / cells
and 0.11	 0.01 in ikbkb fl/flCre/ cells at the basal level, and
1.29	 0.20 in ikbkb fl/flCre / cells and 0.26	 0.05 in ikbkb fl/fl
Figure 2. Infiltration of CD45 or CCR2 cells in APP-transgenic mouse brain. A, Brain sections derived from 6-month-old APP-transgenic mice with (ko) and without (wt) ablation of IKK in
myeloid cells were stained for CD45 (in brown, arrowhead). IKK ablation did not affect the density of CD45 cells in the hippocampus and cortex (B; t test; n
 6 per group). C, CD11b cells were
isolated from 6-month-old IKKko and wt APP-transgenic mice and fluorescently labeled with CD45 antibody for flow cytometry. Histograms show CD45 cells and comparisons between two
groups with control in gray color. D, Columns summarize percentages of CD45 cells in the CD11b brain cell populations (one-way ANOVA; n7 per group). E, Brain sections derived from
6-month-old APP-transgenicmice that weremated to CCR2-RFP knock-inmicewere stained for RFP. A few RFP cells (arrowhead) are in close proximity to cerebral blood vessels, but there are no
RFP cells in the parenchyma. A brain section froma 6-month-old tdTomato-transgenic BM chimera APP-transgenicmousewas used as a positive control, because the chosen antibody recognized
both RFP and tdTomato (F ). TdTomato cells are distributed in the brain parenchyma with typical microglial morphology.
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Cre/ cells after A activation; one-way ANOVA, p  0.05; Fig.
3C,D). However, IKK deficiency did not completely block NF-B
activation byA42 oligomers becauseA significantly increased the
level of phosphorylated p65 in microglia derived from ikbkb fl/fl-
Cre/mice (t test, p 0.05; Fig. 3C,D).
Deficiency of IKK in myeloid cells (microglia) rescues
cognitive deficits in APP-transgenic mice
Because deficiencies in TLR2, MyD88, and IRAK4 in myeloid
cells, especially in microglia, have been shown to ameliorate AD-
like pathology and improve neuronal functions in ADmice (Hao
et al., 2011; Cameron et al., 2012; Liu et al., 2012), we investigated
whether deficiency of IKK in myeloid cells (microglia) im-
proves the cognitive function of APP-transgenic mice. In the
Barnes maze (Hao et al., 2011; Liu et al., 2012), the traveling time
and distance traveled was significantly shorter for all tested mice
when training time increased (Fig. 4A–C; one-way ANOVA, p
0.05). During the test, there were no significant differences in
running speed between various groups of mice or for the same
mice on different training dates (two-way ANOVA, p  0.05).
Therefore, both APP-transgenic (app tg) and non-APP-transgenic
(appwt) littermate mice with different myeloid expressions of IKK
retained the ability to use spatial reference points to learn the loca-
tion of an escape hole (Fig. 4A–C).
There were no differences in traveling time and distance trav-
eled between non-APP-transgenic littermate mice with deficien-
cies in IKK or with wild-type IKK in myeloid cells
(appwtikbkb fl/flCre / and appwtikbkb fl/flCre/; Fig. 4B,C;
two-way ANOVA, p  0.05). However, compared with their
appwtikbkb fl/flCre / and appwtikbkb fl/flCre/ littermates,
6-month-old APP-transgenic mice with wild-type IKK expres-
sion in myeloid cells (app tgikbkb fl/flCre /) spent significantly
more time (Fig. 4B; two-way ANOVA, p  0.05) and traveled
longer distances (Fig. 4C; two-way ANOVA, p  0.05) before
reaching the escape hole. Interestingly, ablation of IKK specifically
in myeloid cells, especially microglia (app tgikbkb fl/flCre/ mice),
completely rescued these cognitive deficits in 6-month-old APP-
transgenic mice as assessed by the Barnes maze test (Fig. 4B,C).
Moreover, in the probe trials, appwtikbkb fl/flCre / and
appwtikbkb fl/flCre/mice visited the escape hole similarly, and
app tgikbkb fl/flCre /mice spent less time around the escape hole
and visited the hole less frequently than did non-APP-transgenic
mice, although the difference did not reach statistical significance
(Fig. 4D,E). Interestingly, compared with app tgikbkb fl/flCre /
mice, app tgikbkb fl/flCre/ mice with IKK deficiency in my-
eloid cells visited the escaping area significantly more frequently
and spent significantly more time there (Fig. 4D,E).
We also used Western blot analysis to quantify the protein
levels of PSD-95 (also known as disks large homolog 4) and pre-
synaptic Munc18–1 in brain homogenates from 6-month-old
APP-transgenic and wild-type littermate control mice. Both
PSD-95 and Munc18–1 levels were markedly lower in
app tgikbkb fl/flCre / mice than in their appwtikbkb fl/flCre /
and appwtikbkb fl/flCre/ littermates (Fig. 4F,G; one-way
ANOVA, p  0.05). Similarly, the amounts of PSD-95
and Munc18–1 proteins did not differ significantly between
appwtikbkb fl/flCre / and appwtikbkb fl/flCre/ mice (Fig.
4F,G; one-way ANOVA, p  0.05). Interestingly, the reduction
in PSD-95 and Munc18–1 proteins due to APP-transgenic ex-
pression was attenuated by the deficiency of IKK in myeloid
cells. The levels of PSD-95 and Munc18–1 proteins were signifi-
cantly higher in brains from app tgikbkb fl/flCre/ mice than in
brains from app tgikbkb fl/flCre / control mice (Fig. 4F,G; one-
way ANOVA, p 0.05).
Deficiency of IKK in myeloid cells (microglia) reduces
inflammatory activation in agedAPP-transgenicmouse brains
Because proinflammatory activation contributes to AD patho-
genesis, we investigated whether a deficiency of IKK in myeloid
cells (microglia)might reduce inflammatory activity in the brain.
We used the stereological technique to estimate the total number
of Iba-1 cells, including microglia and potentially infiltrating
brain macrophages, in the hippocampus and cortex of 6-month-
old APP-transgenic and non-APP-transgenic mice with or with-
out IKK expression in myeloid cells (app tgikbkb fl/flCre/,
app tgikbkb fl/flCre /, appwtikbkb fl/flCre/, and appwtikbkb fl/fl-
Cre / mice). The total number of Iba-1 cells was significantly
higher in APP-transgenic mice than in non-APP-transgenic mice
(Fig. 5A–C; one-way ANOVA, p 0.05). The two groups of trans-
genic mice differed significantly in the total number of Iba-1 cells:
Figure3. IKKablation inhibitsNF-Bactivation inprimary culturedmicroglia. IKKprotein (A,B; t test;n
3pergroup) andphosphorylatedand totalNF-Bp65 (C,D; t test;n
3pergroup)
in the primary cultured microglial cell lysate derived from ikbkb fl/flCre/ (IKKko) and ikbkb fl/flCre / (IKKwt) mice were detected and quantified with Western blotting. For NF-B
activation assays, IKKwt and ko microglia were activated with 10M oligomeric A42 for 12 min.
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app tgikbkb fl/flCre/ mice, 20.46	 0.70  103 cells in the hip-
pocampus and 23.74	 0.86 103 cells in the cortex dorsal to the
hippocampus; app tgikbkb fl/flCre /mice, 25.49	 1.17 103 cells
in the hippocampus and 29.54	 0.89 103 cells in the cortex dor-
sal to the hippocampus (Fig. 5B,C; one-way ANOVA, p  0.05).
However, there was no significant difference in the number of
Iba-1 cells between the two groups of non-APP-transgenic mice
(appwtikbkb fl/flCre/ mice and appwtikbkb fl/flCre / mice; Fig.
5B,C; one-way ANOVA, p 0.05).
We next investigated the mechanisms by which IKK defi-
ciency decreases the number of Iba-1 cells. Because we had
observed no significant difference between groups in the recruit-
mentofmonocyte-derivedbrainmacrophages (Fig. 2),weevaluated
endogenousmicroglial proliferation by costaining Iba-1 andKi67, a
cell-proliferation marker (Liu et al., 2013). Because there were too
few cells, we could not use the stereological technique. As shown in
Figure 5, D and E, there were indeed significantly fewer double-
positive cells in the hippocampus of app tgikbkb fl/flCre/ mice
(3.67	 0.50 cells/mm2) than in that of app tgikbkb fl/flCre /mice
(5.53	 0.77 cells/mm2; t test, p 0.05).
We then used ELISA to quantify TNF- protein levels in the
TBS-soluble brain homogenate derived from 6-month-old APP-
transgenic and nontransgenic mice and found that TNF- pro-
duction was significantly higher in APP mice than in their
non-APP-transgenic littermates (Fig. 5F; one-way ANOVA, p
0.001). A deficiency in IKK in myeloid cells did not affect the
levels of cerebral TNF- protein in non-APP-transgenic mice
(Fig. 5F), but did significantly decrease levels of TNF-protein in
the brain of APP-transgenic mice compared with littermate APP
mice with wild-type IKK expression in myeloid cells (Fig. 5F;
one-way ANOVA, p
 0.002).
We also quantified transcripts of M1-inflammatory gene
markers (tnf-, il-1, inos, and ccl2) and M2-inflammatory gene
markers (il-10, mrc1, arg1, and chi3l3) (Colton et al., 2006) in
the brains of four separate groups of 6-month-old littermate
mice [myeloid IKK: deficient (ikbkb fl/flCre/) and wild-type
Figure 4. Deficiency in IKK inmyeloid cells improves cognitive function in APP-transgenicmice.A, Schematic of the Barnesmaze used. During the training phase, 6-month-old APP-transgenic
mice (APPtg) spentmore time in themaze and traveled longer distances to reach the escape hole than did their non-APP-transgenic littermates (APPwt). Ablation of IKK inmyeloid cells (IKKko)
significantly reduced the traveling time and distance of APPtg mice but not of APPwt mice (B, C; two-way ANOVA; n 9 per group). In the probe trial, APPtg/IKKko mice remained in the target
zone significantly longer and visited the escape hole more frequently than the APPtg/IKKwt mice (D, E; one-way ANOVA; n 9 per group). The amount of PSD-95 and Munc18-1 in the brain
homogenatewas quantifiedwithWestern blotting (F,G). Deficiency inmyeloid IKKwas associatedwith a higher level of PSD-95 andMunc18–1 in the APPtgmouse, but not in the APPwtmouse
(F, G; one-way ANOVA; n 6 per group).
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(ikbkb fl/flCre /) mice; APP-transgenic expression: positive
(app tg) and negative (appwt) mice]. As shown in Figure 5, G and
H, levels of tnf- and il-1 transcripts were significantly higher in
APPmice than in non-APPmice (one-way ANOVA, p 0.05). A
deficiency in IKK inmyeloidcells (microglia) completely abolished
the transcriptional upregulation of tnf- and il-1 by APP-
transgenic expression (one-way ANOVA, p  0.05). In non-APP-
transgenicmice, an IKK deficiency inmyeloid cells did not change
the transcription of tnf- and il-1 genes (Fig. 5G,H; one-way
ANOVA, p 0.05). Neither the transcription of the otherM1 genes
(inos and ccl2) that we tested nor the transcription of theM2 activa-
tion markers differed between myeloid IKK-deficient and wild-
type APP-transgenic or nontransgenic mice (Fig. 5I–N).
In an additional experiment, we isolatedmicroglia and potential
brain macrophages from 6-month-old APP-transgenic mice. We
observed that transcription of the inflammatory gene tnf-, but
not that of other proinflammatory and antiinflammatory genes,
was significantly lower in CD11b cells isolated from
app tgikbkb fl/flCre/mice than in cells from app tgikbkb fl/flCre /
mice (Fig. 5O; t test, p 0.05).
Deficiency of IKK in myeloid cells (microglia) reduces A
load in aged APP-transgenic mouse brains
Because A pathology is considered to be the key mechanism
mediating neuronal death in AD (Mucke and Selkoe, 2012),
we continued to investigate the effects on the cerebral A
load of IKK deficiency in myeloid cells. We separated brain
homogenate from 6-month-old app tgikbkb fl/flCre/ and app t-
gikbkb fl/flCre /mice into 3 TBS-soluble, TBS-T-soluble, and
guanidine chloride-soluble fractions according to our established
protocols (Hao et al., 2011; Liu et al., 2012). Compared with
app tgikbkb fl/flCre /mice, app tgikbkb fl/flCre/mice exhibited
Figure 5. Deficiency of IKK in myeloid cells reduces neuroinflammatory activation in APP-transgenic mice. Six-month-old APP-transgenic mice (APPtg) and their non-APP-transgenic litter-
mates (APPwt)were tested for inflammatory activation.Microglial cell numberswere estimatedwith stereologicalmethods after immunohistochemical staining of Iba-1 (A; in brown). Proliferating
microglia were identified by double staining of Iba-1 and Ki67, which appear in blue nucleus and brown cytoplasm (D; marked with closed arrowheads; pure Iba-1 cells are marked with open
arrowheads). The numbers of Iba-1 cells were significantly smaller in APPtgmice with ablation of myeloid IKK (IKKko) than in those with normal IKK expression (IKKwt). However, IKK
ablationdid not affect the number of Iba-1 cells in APPwtmice (B,C; one-wayANOVA;n
6per group). Thenumber of Iba-1/Ki67double-positive cellswas significantly smaller in APPtg/IKKko
than in APPtg/IKKwtmice (E; t test; n
 6 per group). TNF- protein concentration in brain homogenates derived from APPtg and APPwtmice was determined by ELISA (F; one-way ANOVA; n
6 per group). Inflammatory gene transcripts in the brain (G–N ) and in isolatedmicroglia from 6-month-old APPtgmice (O) weremeasured by quantitative RT-PCR. Both TNF- protein expression
and the number of tnf- and il-1 transcripts in APPtg brains, but not in the APPwt control brains, were significantly reduced by IKK ablation in myeloid cells (F-H; one-way ANOVA; n 9 per
group). Accordingly, the number of tnf- transcripts in APPtg microglia was also significantly reduced by IKK ablation (O; t test; n
 3 per group).
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significantly lower concentrations of A42 and A40 in both
TBS-T-soluble fractions and guanidine chloride-soluble frac-
tions, which were enriched in oligomeric and high-molecular-
weight aggregated A species (Hao et al., 2011; Fig. 6A; t test, p
0.05). Using the commercially available oligomeric A ELISA kit,
we confirmed that the aggregated level of A (106.58	 6.20
pg/mg of wet brain tissue) in TBS-T-soluble brain homogenate
from app tgikbkb fl/flCre/mice was significantly lower than that
Figure 6. Deficiency of IKK in myeloid cells reduces A load in the APP-transgenic mouse brain. The brains of 6-month-old APP-transgenic (APPtg) mice were analyzed for A load. The brain
washomogenizedand separated into TBS-, TBS-T-, andguanidine-soluble fractions. Amounts ofA40andA42weremeasuredbyELISAandnormalized to thehomogenateprotein concentration.
The concentrations of bothA42andA40 inboth TBS-T- andguanidine-soluble fractionswere significantly lower inmyeloid IKK-ablated (ko)APPmice than in IKK-wild-type (wt) controlmice
(A; t test; n
 11 per group). The A volume in thewhole hippocampus and cortexwas estimated after both Congo red staining (B, C) and immunohistochemistrywith humanA-specific antibody
(D, E) and adjusted by volumes of the relevant brain tissues. Myeloid IKK deficiency significantly reduces cerebral A load (t test; n
 8 per group for Congo red staining and n
 13 per group for
immunohistochemistry). F, The ratio of Congo red-stained volume to A-immunohistochemically stained volume is calculated (t test; n
 8 per group).G, The size of A plaquewasmeasured and
the frequency of A plaques with a certain size is shown as a percentage of the total number of plaques (two-way ANOVA, p 0.05; n
 8 per wt or ko group).
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(130.52	 6.20 pg/mg of wet brain tissue) in homogenate from
app tgikbkb fl/flCre /mice (t test, p
 0.036). In the TBS-soluble
brain homogenate fraction, which contained most of the mono-
meric A species (Hao et al., 2011), a deficiency in IKK in
myeloid cells did not significantly affect A concentrations (Fig.
6A; t test, p 0.05).
We used Congo red staining and immunohistochemical anal-
ysis to determine the A load in the brain. As shown in Figure 6,
B andD, the extent and morphology of the Congophilic amyloid
load or of antibody-labeled diffused A or A plaques with dense
cores were not changed by a deficiency in IKK in the myeloid
cell lineage. When we measured A volume (adjusted by the
volume of analyzed tissues) with the stereological Cavalieri
method (Gundersen and Jensen, 1987), we observed that, after
ablation of IKK in myeloid cells, the volume of Congophilic
A load (0.074%	 0.009% in the hippocampus and
0.143%	 0.015% in the cortex) was significantly reduced
(to 0.048%	 0.006% in the hippocampus, p 
 0.038, and
0.095%	 0.012% in the cortex, p 
 0.019; Fig. 6B,C; t test for
relevant comparisons). Similarly, the volume of immunoreactive
A load was markedly higher in app tgikbkb fl/flCre / mice
(2.687%	 0.020% in the hippocampus and 2.801%	 0.234% in
the cortex) than in app tgikbkb fl/flCre/mice (2.062%	 0.152%
in the hippocampus, p 
 0.027, and 2.139%	 0.178% in the
cortex, p 
 0.041; Fig. 6D,E; t test for relevant comparisons).
Because Congo red typically binds to the  sheet structure of
A plaques (Lorenzo and Yankner, 1994), we calculated the
ratio of volumes of Congo red staining to volumes of immu-
nohistochemical staining, which were not altered by the defi-
ciency in myeloid IKK (Fig. 6F; t test, p  0.05), a fact
suggesting that the ablation of myeloid IKK does not affect
A aggregation. Furthermore, we quantified A deposits in
the hippocampus and analyzed the distribution of their size.
As shown in Figure 6G, IKK ablation in the myeloid cell
lineage tended to shift A plaques from large to small, al-
though the difference in the distribution of plaque size be-
tween IKK-deficient and wild-type mice was not statistically
significant (two-way ANOVA, p  0.05).
Deficiency in IKK enhances microglial andmacrophage
recruitment toward A deposits and A internalization
Given that a deficiency in IKK in microglia reduced both in-
flammatory activation and A load in the APP-transgenicmouse
brain, we hypothesized that IKK deficiency might enhance A
clearance by internalization into microglia or macrophages. Be-
cause it is difficult to measure intracellular A directly in the
brain, we first counted microglia and macrophages interacting
with A deposits and found that significantly more Iba-1 cells
were recruited to the A deposits in app tgikbkb fl/flCre/ mice
than to the A deposits in their app tgikbkb fl/flCre / littermates
(Fig. 7A,B; t test, p 
 0.008), a finding consistent with our pre-
vious findings in ADmice with a deficiency inMyD88 inmyeloid
cells (Hao et al., 2011). However, the amoeboid morphology of
microglia surrounding A appeared not to be changed by my-
eloid IKKdeficiencywhen the IKK-deficient cells were tracked
by Cre-mediated GFP expression (Fig. 7C). IKK deficiency
significantly upregulated the transcription of A-cleaning
scavenger receptor A (Frenkel et al., 2013) in the brains of APP-
transgenic mice, but not in the brains of their non-APP-
transgenic littermates (Fig. 7D; one-way ANOVA, p  0.05).
CD36 transcriptionwas lower in app tgikbkb fl/flCre /mice than
in appwtikbkb fl/flCre / littermate controls (Fig. 7E; one-way
ANOVA, p 0.05), a finding consistent with the observations of
El Khoury’s group (Hickman et al., 2008). Interestingly, a defi-
ciency in IKK in microglia was associated with the complete
recovery of CD36 expression in the brains of APP-transgenic
mice (Fig. 7E; one-way ANOVA, p 0.05), but had no effects on
CD36 transcription in non-APP-transgenic mice (Fig. 7E; one-
way ANOVA, p 0.05).
In further experiments, we challenged primary cultured mi-
croglia with HiLyte Fluor 488-labeled A42 enriched in oligo-
meric and fibrillar species (Fig. 8A) to model the A species in
TBS-T-soluble and guanidine-soluble brain homogenates.When
microglia were treatedwith aggregated A at a concentration of 1
M, internalization was detectable within 1 h and levels of inter-
nalized A increased as the incubation time increased (Fig.
8B,C). Significantly more oligomeric A42 than fibrillar A42
was internalized bymicroglia (with orwithout IKK expression),
asmeasured bymFI (Fig. 8B; two-way ANOVA, p 0.001). After
cells were incubated with A42 for 3 h, the mFI of cells treated
with A oligomers decreased more quickly than did that of mi-
croglia treated with A fibrils. This difference could be due to the
difference in the efficiency of degradation and extracellular re-
lease between A oligomers and fibrils inmicroglia (Chung et al.,
1999; Yamamoto et al., 2008).
Comparison of the internalizing capability of IKK-deficient
and wild-type microglia showed that IKK deficiency signifi-
cantly increased the uptake of A42 oligomers at a concentration
of 1 M, but not of A fibrils. This difference remained when
A42 treatment was extended to 24 h (Fig. 8B,C; two-way
ANOVA, p 0.001). Interestingly, when microglia were treated
with oligomeric A42 at a concentration of 0.2 M, IKK defi-
ciency did not enhance A internalization (Fig. 8B,C; two-way
ANOVA, p  0.05). Similar results were seen in internalization
assays with BM-derived macrophages, in which IKK-deficient
macrophages showed a significantly higher uptake of A than
IKK-wild-typemacrophages when cells were treatedwith oligo-
meric A42 at concentrations of 1 or 10M. This A internaliza-
tion enhanced by IKK deficiency disappeared when oligomeric
A42 was administered at a concentration of 0.5 M or when
fibrillar A42 was administered at a concentration of 1 M (data
not shown).
To determine whether elevated inflammatory activation
might be inversely related to the internalization of A into mi-
croglia (Hao et al., 2011; Liu et al., 2012), we performed two
additional experiments. First, we analyzed the pathological
changes in 3-month-old APP-transgenic mice with or without
IKK ablation in myeloid cells as controls for the 6-month-old
AD mice that we described in the sections “Deficiency of IKK
in myeloid cells (microglia) reduces inflammatory activation in
aged APP-transgenic mouse brains” and “Deficiency of IKK in
myeloid cells (microglia) reduces A load in aged APP-
transgenic mouse brains.” A deficiency in myeloid IKK neither
changed cerebral transcripts of tnf-, il-1, and inos genes nor
alteredA concentrations in all TBS-soluble, TBS-T-soluble, and
guanidine chloride-soluble brain homogenate fractions (data not
shown). Second, we measured the inflammatory activation of
cultured microglia during internalization of A over a 6 h inter-
val. As shown in Figure 8,D and E, IKK deficiency significantly
suppressed inflammatory gene (e.g., tnf- and il-1) transcrip-
tion triggered by oligomeric A at a concentration of 1M (two-
way ANOVA, p  0.05). Microglial inflammatory gene
transcription was not significantly induced by fibrillar A42 at a
concentration of 1 M or by oligomeric A42 at a concentration
of 0.2 M (Fig. 8D,E; two-way ANOVA, p 0.05).
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Inhibition of TGF--SMAD2/3 signaling could be involved in
microglial A internalization enhanced by IKK deficiency
Because it has been reported that blocking either CD40 or the
TGF- signaling cascade in ADmice leads to a reduction in both
inflammatory activation and A load in the brain (Tan et al.,
1999 and 2002; Town et al., 2008), the same phenomenon we
observed in myeloid IKK-deficient AD mice, we decided to in-
vestigate whether IKK modulates CD40 and TGF- signaling.
Indeed, a deficiency in myeloid IKK significantly decreased
transcription levels of TGF- receptor types 1 and 2 (TGF-R1
and -R2) in microglia isolated from APP-transgenic mice (Fig.
8G; t test, p 0.05), although IKK deficiency did not change the
transcription level of these two receptors or of TGF-1 in the
entire brain (Fig. 8F; t test, p 0.05). In culturedmicroglia, IKK
deficiency reduced tgf-1 transcription at the basal level and re-
duced both tgf-1 and tgf-r1 transcription after challenge with
oligomeric A42 at a concentration of 1 M (Fig. 8H; t test, p
0.05). Notably, we observed that IKK deficiency inhibited
SMAD2 phosphorylation but did not change SMAD5 phosphor-
ylation in microglia in response to stimulation with TGF-1 at a
concentration of 1 or 10 ng/ml (Fig. 8I–K; two-way ANOVA).
However, CD40 gene transcription was not changed by IKK
deficiency in either adult or culturedmicroglia (data not shown).
Thereafter, we tested whether A internalization in microglia
was increased by blockade of TGF--SMAD2/3 signaling, as de-
scribed previously (Town et al., 2008). Two ALK-5 inhibitors,
SB-505124 and SB-431542, at concentrations of 1 and 10M, had
been shown to inhibit both SMAD2/3 and SMAD1/5/8 signaling
in response to exogenous TGF-1 activation (Town et al., 2008).
We observed that both SB-505124 and SB-431542 at concentra-
tions of 0.1 and 0.02 M reduced SMAD2 phosphorylation, but
did not markedly affect SMAD5 phosphorylation in microglia
after the same challenge with TGF-1 (Fig. 8L). This partial in-
hibition was comparable to the inhibition caused by IKK defi-
Figure7. IKKdeficiency increasesmicroglial/brainmacrophage recruitment towardAdeposits in theAPP-transgenicmousebrain. The6-month-oldAPP-transgenic (APPtg)mousebrainwas
analyzed for the interaction betweenA andmicroglia and brainmacrophages under confocalmicroscopy after immunofluorescent stainingwith antibodies against A and Iba-1 (A; A in red and
Iba-1 in green). The numbers of microglia and macrophages that colocalized with A were counted and adjusted by A volume. More IKK-ablated (ko) than wild-type (wt) microglia and
macrophageswere recruited to A deposits (B; t test; n
 6 per group). C, IKK-ablatedmicroglia andmacrophageswere tracked by GFP expression. After costaining GFP in green and Iba-1 in red
fluorescence, microglia and macrophages expressing both proteins appeared in yellow (closed arrowheads) and cells expressing Iba-1 alone are shown in red (open arrowhead). A plaques were
stained in blue color in the bright field and appeared as black holes under confocal microscopy (marked with asterisks). Therefore, IKK ablation does not change the amoeboid morphology of
microglia andmacrophages contactingAplaque. The transcription of scavenger receptor A (sra) and cd36wasmeasuredwith quantitative RT-PCR andwas upregulated bymyeloid IKKdeficiency
in APPtg mouse brains, but not in APP-wild-type (APPwt) mouse brains (D, E; one-way ANOVA; n 9 per group).
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Figure 8. IKK deficiency blocks TGF--SMAD2/3 signaling and increases microglial internalization of oligomeric A42. A, Aggregating patterns (o, oligomeric; f, fibrillar) of HiLyte Fluor
488-labeled A42. B, C, Line curves showing the internalization of 1 or 0.2M oligomeric A42 (oA) and 1M fibrillar A42 (fA) by primary cultured microglia derived from IKK-ablated
(IKKko) andwild-type (IKKwt)mice for various time periods (two-way ANOVA; n
 3 per group).D, E, Histograms showing the inflammatory gene transcripts in primarymicroglia 6 h after the
A internalization (t test; n 6 per group). F–H, Transcripts of tgf-1, tgf-r1, and r2 genes in the entire hippocampus and cortex in adult microglia isolated from APP-transgenic mice and in
cultured primary microglia with and without treatment of 1M oAweremeasured using real-time PCR (t test; n 5 per group). Primary cultured IKKwt and IKKkomicroglia were activated
with TGF-1 at 0, 1, and 10 ng/ml for 30min (I–K ); IKKwtmicroglia were also treatedwith SB-505124 and SB-431542 at 0, 0.02, and 0.1M and thenwith 1 ng/ml TGF-1 for 30min (L). After
stimulation, the phosphorylated and total SMAD2 and SMAD5 proteins were detected by Western blotting. The ratios of phospho-/total SMAD2 and SMAD5 reflect SMAD2/3 and SMAD1/5/8
signaling. Therefore, the IKK ablation specifically blocks SMAD2/3 signaling without affecting SMAD1/5/8 signaling (J, K; two-way ANOVA, n
 4 per group). SB-505124 and SB-431542 at 0.02
and 0.1M inhibit SMAD2/3 signaling and exert less effect on SMAD1/5/8 signaling (L).M,N, IKKwtmicroglia were pretreatedwith SB-505124 and SB-431542 at 0, 0.02, and 0.1M for 1 h and
then incubatedwith 1M fluorescent oA for 6 h in the presence of inhibitors. The internalization of oAwas assayedwith flow cytometry (two-way ANOVA followed by post hoc tests, *p 0.05
and **p 0.01 vs the A internalization without inhibitor treatment; n
 4 per group).
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ciency, as described in the preceding paragraph. Interestingly, the
inhibitor-treated cultured microglia internalized significantly
more oligomeric A42 aggregates, in a dose-dependent manner,
than did the microglia without special treatment (Fig. 8M,N;
two-way ANOVA, p 0.05). The concentrations that promoted
A internalization were between 0.5 M and 20 nM; the maximal
effect was induced by a concentration of 20 nM (Fig. 8M,N; two-
way ANOVA followed by post hoc tests, p 0.05). At higher and
lower concentrations (1 M and 4 nM, respectively), the inhibi-
tors failed to promote A internalization.
Deficiency in IKK in myeloid cells neither increases A
clearance through brain-to-blood transportation and
endogenous degradation nor reduces amyloidogenic APP
metabolism
Deane et al. (2004) reported that altered communication of A
between the brain interstitial fluid and the peripheral blood-
stream affects cerebral A load. Peripheral myeloid cells could
clear A in the perivascular area so as to reduce A deposition in
the parenchyma (Hawkes and McLaurin, 2009; Mildner et al.,
2011). We observed that neither the volume of A that was de-
posited in the blood vessels nor the number of vessels that tested
positive for A deposits differed between myeloid IKK-
deficient and wild-type APP-transgenic mice (Fig. 9A–C; t test,
p  0.05). We also measured A levels in the plasma and the
expression of RAGE and LRP1 in the brain, two receptors that act
as shuttles to transport A across the blood–brain barrier (Shi-
bata et al., 2000; Deane et al., 2003 and 2004). As shown in Figure
9, neither plasma A40 and A42 concentrations in APP-
transgenic mice (Fig. 9F) nor receptor expression in APP-
transgenic and nontransgenic mouse brains (Fig. 9D,E) was
affected by IKK deficiency in myeloid cells (t test, p 0.05).
To determinewhether IKK deficiency inmyeloid cells affects
A production in APP-transgenic mice, we measured the activi-
ties of -secretase and -secretase, the two main enzymes that
cleave APP to produce A (Mucke and Selkoe, 2012). Surpris-
ingly, neither -secretase activity nor -secretase activity was
changed by IKK deficiency (data not shown). Quantitative
RT-PCR investigation of the A-degrading enzyme neprilysin
and the insulin-degrading enzyme (Leissring et al., 2003; Miners
et al., 2008) showed no significant increase in the transcription of
nep and ide genes in app tgikbkb fl/flCre/ mice compared with
app tgikbkb fl/flCre / littermate controls (data not shown), a
finding suggesting that microglial IKK deficiency has no effect
on A catabolism.
Discussion
Microglial activation exerts both toxic and protective effects on
neurons in AD pathogenesis, and TLRs and their downstream
signaling molecules have been observed to control microglial be-
haviors that lead to these controversial effects (Tahara et al., 2006;
Reed-Geaghan et al., 2010; Hao et al., 2011; Lim et al., 2011;
Michaud et al., 2011 and 2012; Song et al., 2011; Cameron et al.,
2012; Liu et al., 2012). In this study, we demonstrated that a
deficiency in IKK in myeloid cells, especially in endogenous
microglia, simultaneously reduces inflammatory activation and
A load in the brain and improves cognitive function inADmice.
These findings corroborate the results of our earlier studies of the
deficiency of myeloid TLR2 or MyD88 in APP-transgenic mice
(Hao et al., 2011; Liu et al., 2012).
Figure 9. Deficiency of IKK inmyeloid cells does not increase A clearance through brain-to-blood transportation. The 6-month-old APP-transgenic (APPtg) and non-APP-transgenic (APPwt)
littermatemice with (IKKko) andwithout IKK ablation (IKKwt) inmyeloid cells were analyzed for cerebral vascular A deposits after tissues were costainedwith Congo red and collagen type
IV antibodies (A–C) and for transcription of lrp1 and rage in the brain with quantitative RT-PCR (D, E). Concentrations of A40 and A42 in the plasma from IKKko and IKKwt APPtgmice were
quantifiedbyELISA (F ). Neither volumesof Congo red stainingnornumbers of Congo red-positivebloodvessels differedbetween IKKkoand IKKwtAPPtgmice (t test,p0.05;n
8pergroup).
Similarly, neither gene transcription (D, E) nor plasmaA concentrations (F ) was significantly changed by the IKK deficiency (one-way ANOVA for gene transcripts, p 0.05; t test for plasmaA
concentrations between IKKko and IKKwt mice, p 0.05; n 9 per group).
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To the best of our knowledge, we were the first to use the
Cre-Lox technique in cross-breeding experiments to condition-
ally delete the protein of interest in APP-transgenic mice. This
deletion allows us to investigate in detail the functions of this
protein in AD pathogenesis in a specific tissue and within a cer-
tain time frame. We investigated IKK in microglia by specifi-
cally ablating IKK in myeloid cells of APP-transgenic mice,
thereby excluding any confounding effects from neuronal IKK.
Neuronal IKK has been reported to activate neuronal NF-B,
thus modifying A generation and the degeneration and plastic-
ity of neurons (Kaltschmidt et al., 1997; Fridmacher et al., 2003;
He et al., 2007; Kaltschmidt and Kaltschmidt, 2009; Gutierrez
and Davies, 2011).
However, in our AD animalmodel, the ikbkb gene was deleted
not only in endogenousmicroglia, but also in peripheral myeloid
cells (Clausen et al., 1999; Goldmann et al., 2013). One subset of
myeloid cells potentially circulates to the brain parenchyma and
serves as brain macrophages (Hao et al., 2011). In our APP-
transgenic mouse brains we observed a small population of
CD45 cells the distribution of which was localized within one
brain region instead of around most A deposits, a finding indi-
cating that these cells are not activated endogenous microglia.
These CD45 cells are also neither neutrophils nor T lympho-
cytes because they do not express neutrophil or CD3 markers.
Therefore, this cell population may be brain macrophages. Sur-
prisingly, the number of CD45 cells in this population is very
limited (2% of Iba-1 cells, as estimated on the basis of our
observations; Hao et al., 2011; Liu et al., 2012; Xie et al., 2013).
Moreover, flow cytometry showed that 2% of CD11b brain
cells are CD45, not only in IKK-deficient and wild-type APP-
transgenic mice, but also in non-APP-transgenic mice. There-
fore, the recruitment of potential brain macrophages appears to
be independent of neuroinflammatory status and of IKK ex-
pression in AD mice.
Brain macrophages have been shown to originate from
CCR2 monocytes (Mildner et al., 2007; Varvel et al., 2012). In
another APP-transgenic mouse model, one allele of the ccr2 gene
was replacedby theRFP-encoding sequence,whereas theother allele
expressed CCR2 to exert full cellular physiological function (Saede-
rup et al., 2010). In the brains of these animals (app tg/ccr2-rfp/
mice), no CCR2-RFP cells were observed to infiltrate the brain
parenchyma, a finding further corroborating the hypothesis that
the recruitment of brain macrophages in AD mice is limited.
APP-transgenic mouse brains that have not been preconditioned
by irradiation are devoid of parenchymal peripherally infiltrated
macrophages (Mildner et al., 2011; Kierdorf et al., 2013), a con-
dition that makes it unlikely that IKK-ablated brain macro-
phages can affect A pathology in the brain parenchyma.
In the perivascular area, peripheral myeloid cells can interact
with A and modify the cerebral A load (Hawkes and McLau-
rin, 2009;Mildner et al., 2011). In our ADmousemodels, neither
the concentration of plasma A (especially A42) and TNF-
nor the volume of A deposited in the blood vessels was changed
by the ablation of IKK in the myeloid cells. Therefore, although
the effects of peripheral myeloid cells on A pathology cannot be
completely excluded, the anti-AD phenotype observed in our
study appears to result primarily from a deficiency in IKK in the
endogenous microglia.
As we reviewed in the Introduction, whether microglial acti-
vation serves beneficial or detrimental effects in AD pathogenesis
is still strongly under debate. The most contentious issue is
whether the inhibition of innate immunity simultaneously atten-
uates A pathology and proinflammatory activation. Our previ-
ous studies focusing on TLR2 (Liu et al., 2012) andMyD88 (Hao
et al., 2011) and the present study addressing IKK have consis-
tently given a positive answer to this question. Indeed, other pub-
lished observations show that a decrease in the cerebral A load
accompanies neuroinflammatory reduction, whether caused by a
deficiency in CD40 ligand (Tan et al., 1999 and 2002), IRAK4
(Cameron et al., 2012), NLRP3 (Heneka et al., 2013), orMrp14 (a
neuroinflammation-amplifying protein; Kummer et al., 2012),
by blockingTGF--SMAD2/3 signaling (Town et al., 2008), or by
stimulating PPAR and retinoid X receptors (Yamanaka et al.,
2012). The enhancement of A clearance results from reduced
inflammatory activation rather than from direct effects of the
innate immune molecules per se. In the brains of 3-month-old
APP-transgenicmice and in themicroglial/macrophage internal-
ization assays with A at low concentrations (e.g., 0.2 M), the
inflammatory activation level is low. Therefore, the presence or
absence of MyD88 or IKK does not affect A internalization
(Hao et al., 2011).
However, it has been shown that inflammatory activation by
the systemic administration of TLR4 ligands can facilitate micro-
glial internalization of A, which decreases the A burden in
APP-transgenic mice (Michaud et al., 2013). These results raise
an apparent discrepancy with our findings. In our study, we ob-
served that IKK deficiency specifically blocks TGF--SMAD2/3
signaling but does not affect the SMAD1/5/8 pathway in micro-
glia. Microglial SMAD1/5/8 signaling is constitutively active.
Town et al. (2008) reported that SMAD2/3 signaling inhibits
macrophage uptake of A, whereas SMAD1/5/8 signaling pro-
motes it; however, an IKK deficiency in themicroglia of our AD
mice may have attenuated the inhibitory effects of SMAD2/3
signaling, thereby enhancing microglial clearance of A in the
brain. Using cultured microglia, we have confirmed that the
pharmacological inhibition of SMAD2/3 signaling increases A
internalization. In Michaud’s AD mice, microglial SMAD1/5/8
signaling could be further induced by TLR4-mediated inflamma-
tory activation, so that the A internalization-promoting effect is
relatively stronger than the inhibitory effect contributed by
SMAD2/3. Therefore, activation of the SMAD1/5/8 signaling cas-
cade by exogenous stimulatorsmay resolve this apparent discrep-
ancy. The hypothesis that the signaling balance between
SMAD2/3 and SMAD1/5/8modulates microglial A internaliza-
tion could function also in other AD mice deficient in NLRP3
(Heneka et al., 2013) or with PPAR activation (Yamanaka et al.,
2012), because a deficiency in NLRP3 attenuates (Wang et al.,
2013) SMAD2/3 phosphorylation in the kidney epithelium,
whereas a deficiency in PPAR increases SMAD2/3 phosphory-
lation in embryo fibroblasts (Ghosh et al., 2008). Additional
studies are needed to further investigate whether this TGF- hy-
pothesis is a general rule in enhanced microglial A clearance
after the inhibition of innate immune signaling and exactly how
TGF- regulates microglial endocytosis.
It is clear that microglial proinflammatory activation contrib-
utes to AD pathology, and both M1 and M2 inflammatory acti-
vation markers have been observed in AD human and mouse
brains (Colton et al., 2006).M1 inflammatory activation contrib-
utes to neuronal degeneration (Akiyama et al., 2000;Wyss-Coray
and Rogers, 2012). Inhibiting the typical proinflammatory sig-
naling by IL-12/IL-23 (VomBerg et al., 2012) and IL-1 (Heneka
et al., 2013) has been reported to attenuate AD pathology and
cognitive deficits. In another study, adoptive transfer of
interferon--producing A-specific T lymphocytes into AD
mice severely exacerbated ADpathogenesis (Browne et al., 2013).
In contrast,M2 inflammatory activation appears to produce ben-
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eficial effects in AD by facilitating neurotoxic inflammatory res-
olution and promoting neuronal protection and regeneration
(Colton et al., 2006; Qian et al., 2006; Martinez et al., 2009; Ma et
al., 2010; Sharma et al., 2011; Liu et al., 2012). In our studies,
ablation of microglial MyD88 and IKK reduced only M1 in-
flammatory activation without affecting M2 activation in the
APP-transgenic mouse brain (Hao et al., 2011). In ADmice with
a deficiency in CD14 (Reed-Geaghan et al., 2010), TLR2 (Liu et
al., 2012), or IRAK4 (Cameron et al., 2012), microglia were
skewed from M1 to M2 inflammatory activation, although the
underlying mechanisms were not explained.
In this study, a deficiency in IKK in myeloid cells did not
appear to affect A generation and A efflux from the brain
parenchyma. This observation was surprising in light of the fact
that neuroinflammation has been reported to change -secretase
and -secretase expression and activity (Sheng et al., 2003; He et
al., 2007; Xie et al., 2013) and to alter the A transporter function
in the blood–brain barrier (Erickson et al., 2012).
In summary, our study shows that the signaling cascade of
TLRs-MyD88-IRAK4-IKK mediates A-triggered microglial
inflammatory activation. Ablation of IKK inhibits detrimental
neuroinflammation and facilitates beneficial A clearance,
thereby improving neuronal function in AD mice. These results
contribute to a better understanding of AD pathogenic mecha-
nisms thatmay eventually translate to therapeutic options for the
prevention or treatment of AD progression.
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